anti-ITGB6 ProTriTAC / Merck (MSD) - LARVOL DELTA

Harpoon Therapeutics Presents Data for New ProTriTAC Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023 (GlobeNewswire) - "Harpoon Therapeutics...presented preclinical data on two new development candidates from the proprietary ProTriTAC™ platform in TROP2- and ITGB6-expressing solid tumors in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting....In rodent established tumor models, ITGB6 ProTriTAC showed efficient prodrug activation and potent anti-tumor activity in vivo with complete tumor eradication at doses as low as 30 µg/kg. In cynomolgus monkeys, ITGB6 ProTriTAC showed favorable pharmacokinetic and safety profiles and was well-tolerated up to 540 µg/kg, the highest dose tested."

Preclinical • Oncology • Solid Tumor